Progress and prospects for herpesvirus vaccination using gB antigens

Area of Science:

• Virology
• Immunology
• Vaccine Development

Background:

• Herpesviruses, including EBV, HCMV, and HSV, cause significant disease, necessitating new vaccines.
• Surface glycoproteins mediate herpesvirus entry via membrane fusion, with Glycoprotein B (gB) acting as a conserved fusogen.
• Previous gB-based vaccines, like one for HCMV, showed partial efficacy, highlighting gB's potential.

Purpose of the Study:

• To review current knowledge on herpesvirus Glycoprotein B (gB) as a vaccine antigen.
• To assess gB's structure, function, and role in herpesvirus entry.
• To evaluate antibody interactions with gB and results from gB-based vaccine studies.

Main Methods:

• Literature review of herpesvirus gB structure and function.
• Analysis of in vitro studies on antibody-gB interactions.
• Review of in vivo studies involving gB-based vaccines.

Main Results:

• Herpesvirus entry relies on glycoproteins, with conserved gB acting as the fusogen.
• Stabilization of gB's pre-fusion conformation may enhance immunogenicity.
• gB-targeting vaccines have received less recent attention than those targeting other glycoproteins.

Conclusions:

• gB remains a promising antigen for future herpesvirus vaccines.
• Further research into gB structure and antibody responses is crucial.
• gB-based vaccines may offer a complementary or alternative approach to current vaccine strategies.